---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-144956"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:36:31.748648+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics secures $200M immediate funding from Royalty Pharma; restructures aficamten royalty

## Summary
- Received $50M upfront from Tranche 6 term loan and $100M from 2024 DFA; plus $50M from CK-586 RPA; total $200M immediate cash.
- Aficamten royalty restructured: RPI gets 4.5% up to $5B net sales (was $1B), then 1% above $5B (was 3.5%).
- Optional $175M Tranche 7 term loan if FDA approves aficamten for HCM by Dec 31, 2025; repayment at 190% of principal.
- CK-586 RPA provides up to $200M total; RPI funds 50% of R&D costs after Phase 3 start; receives 1-4.5% royalty plus milestone payments.
- Stock Purchase Agreement allows Cytokinetics to require RPI to buy $50M shares in next equity financing (min $250M gross) by Aug 20, 2024.

## SEC filing metadata
- accession: 0001193125-24-144956
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312524144956/0001193125-24-144956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312524144956/d796481d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-144956
- JSON: https://secwatch.observer/filing/0001193125-24-144956.json
- Plain text: https://secwatch.observer/filing/0001193125-24-144956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.